Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Inventors

Nair, Hareesh • Santhamma, Bindu • Nickisch, Klaus

Assignees

Evestra Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10053485-B2

Patent

Publication Date

2018-08-21

Expiration Date


Abstract

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Core Innovation

The invention relates to cytotoxic small molecule compounds that inhibit leukemia inhibitory factor (LIF) and MDM2, with downstream signaling involving STAT3 and p53. The document frames the underlying problem as an unmet need in cancer and references cancer progression contexts that include cancer stem cells, carcinoma-associated fibroblasts, and hypertrophic fibroblasts.

The core chemical embodiments are provided as cytotoxic small molecule compounds defined by chemical structures (I)–(IV), using variable substituents (R1/R2/R3/R4/R5/R6). The document also defines a synthetic intermediate (V) that includes a triisopropylsilyl (TIPS) protecting group and describes example compound EC330, including a TIPS-protected acetylenic hydrogen and TBAF in the route context.

The described synthesis context also provides difluorinated estrane derivatives and a key intermediate of structure (V) for cytotoxic steroidal compounds. The compounds include a propynyl substituent at C-17, including TIPS-protected difluoroalkynes and deprotected free difluoro propyne analogs, together with additional derivatives varying at aryl para-substituents.

Beyond the chemical preparation, the document reports biological activity for EC330 and related EC compounds, including low-nanomolar cytotoxicity, inhibition of soft-agar colony formation and HUVEC tube formation, apoptosis induction, xenograft tumor burden reduction, and mechanistic statements involving LIF/STAT3 and p53/MDM2 modulation. It also states LIF-specific cytotoxicity in LIF-overexpressing cells and a potential contraceptive use through LIF inhibition during embryo implantation.

Claims Coverage

The provided independent claims define compounds by structural formulas (I) and (V) with substituent constraints. Across the independent claims, the inventive features are concentrated in structural limitations for R2/R3/R4/R5 in structure (I) and the restricted scope of R5 in structure (V).

A compound having the structure (I) with defined substituent constraints

R2 and R3 are F; R4 is H, alkyl, —CH2—OH, —CO2R6, or —CON(R6)2; and R5 is alkyl, alkenyl, aryl, or cycloalkyl.

A compound having the structure (V) with restricted substituent scope

R5 is alkyl, alkenyl, cycloalkyl, or aryl.

The claim coverage is structural and covers compounds defined by structure (I) with fixed fluorine substitution for R2 and R3, constrained options for R4, and an R5 scope limited to alkyl, alkenyl, aryl, or cycloalkyl, together with compounds defined by structure (V) where R5 is restricted to alkyl, alkenyl, cycloalkyl, or aryl.

Stated Advantages

Potent low-nanomolar cytotoxicity in the NCI-60 panel and multiple cancer cell lines.

Inhibition of soft-agar colony formation.

Inhibition of HUVEC tube formation with anti-angiogenic effect.

Apoptosis induction.

Reduction of xenograft tumor burden.

LIF-specific cytotoxicity in LIF-overexpressing cells.

Potential contraceptive use through LIF inhibition during embryo implantation.

Mechanistic modulation including SMAD/TGF-beta blocking, increased p53 with reduced MDM2, and decreased STAT3 phosphorylation.

Documented Applications

Cancer-related use indicated by cytotoxic activity, inhibition of soft-agar colony formation and HUVEC tube formation, xenograft tumor burden reduction, and apoptosis induction in association with LIF/STAT3 and p53/MDM2 modulation.

Potential contraceptive use through LIF inhibition during embryo implantation.

Use in cancer models described as human triple negative breast cancer (TNBC) xenograft and ovarian cancer xenograft models.

Use in anti-angiogenesis assessment using HUVEC Matrigel tube-formation assays.

Use in soft agar colony formation assessment for tumorigenicity inhibition.

Use in NCI-60 style screening with GI50, TGI, and LC50 across multiple cancer panels.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.